Literature DB >> 25522789

Genomic Knockout of Endogenous Canine P-Glycoprotein in Wild-Type, Human P-Glycoprotein and Human BCRP Transfected MDCKII Cell Lines by Zinc Finger Nucleases.

Dominik Gartzke1, Jürgen Delzer, Loic Laplanche, Yasuo Uchida, Yutaro Hoshi, Masanori Tachikawa, Tetsuya Terasaki, Jens Sydor, Gert Fricker.   

Abstract

PURPOSE: To investigate whether it is possible to specifically suppress the expression and function of endogenous canine P-glycoprotein (cPgp) in Madin-Darby canine kidney type II cells (MDCKII) transfected with hPGP and breast cancer resistance protein (hBCRP) by zinc finger nuclease (ZFN) producing sequence specific DNA double strand breaks.
METHODS: Wild-type, hPGP-transfected, and hBCRP-transfected MDCKII cells were transfected with ZFN targeting for cPgp. Net efflux ratios (NER) of Pgp and Bcrp substrates were determined by dividing efflux ratios (basal-to-apical / apical-to-basal) in over-expressing cell monolayers by those in wild-type ones.
RESULTS: From ZFN-transfected cells, cell populations (ko-cells) showing knockout of cPgp were selected based on genotyping by PCR. qRT-PCR analysis showed the significant knock-downs of cPgp and interestingly also cMrp2 expressions. Specific knock-downs of protein expression for cPgp were shown by western blotting and quantitative targeted absolute proteomics. Endogenous canine Bcrp proteins were not detected. For PGP-transfected cells, NERs of 5 Pgp substrates in ko-cells were significantly greater than those in parental cells not transfected with ZFN. Similar result was obtained for BCRP-transfected cells with a dual Pgp and Bcrp substrate.
CONCLUSION: Specific efflux mediated by hPGP or hBCRP can be determined with MDCKII cells where cPgp has been knocked out by ZFN.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25522789     DOI: 10.1007/s11095-014-1599-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  52 in total

Review 1.  Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters.

Authors:  Supratim Choudhuri; Curtis D Klaassen
Journal:  Int J Toxicol       Date:  2006 Jul-Aug       Impact factor: 2.032

Review 2.  Membrane transporters in drug development.

Authors:  Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang
Journal:  Nat Rev Drug Discov       Date:  2010-03       Impact factor: 84.694

3.  Localization of multidrug transporter substrates within model membranes.

Authors:  Alena Siarheyeva; Jakob J Lopez; Clemens Glaubitz
Journal:  Biochemistry       Date:  2006-05-16       Impact factor: 3.162

4.  Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.

Authors:  Konstantin Kuteykin-Teplyakov; Carlos Luna-Tortós; Kamila Ambroziak; Wolfgang Löscher
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

5.  Chromosomal variation and the origin of drug-resistant mutants in mammalian cell lines.

Authors:  M Terzi
Journal:  Proc Natl Acad Sci U S A       Date:  1974-12       Impact factor: 11.205

6.  Highly efficient endogenous human gene correction using designed zinc-finger nucleases.

Authors:  Fyodor D Urnov; Jeffrey C Miller; Ya-Li Lee; Christian M Beausejour; Jeremy M Rock; Sheldon Augustus; Andrew C Jamieson; Matthew H Porteus; Philip D Gregory; Michael C Holmes
Journal:  Nature       Date:  2005-04-03       Impact factor: 49.962

7.  Efficient gene targeting in Drosophila with zinc-finger nucleases.

Authors:  Kelly Beumer; Gargi Bhattacharyya; Marina Bibikova; Jonathan K Trautman; Dana Carroll
Journal:  Genetics       Date:  2006-02-01       Impact factor: 4.562

8.  P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.

Authors:  Nienke A de Vries; Jin Zhao; Emily Kroon; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen
Journal:  Clin Cancer Res       Date:  2007-11-01       Impact factor: 12.531

Review 9.  Targeting multidrug resistance in cancer.

Authors:  Gergely Szakács; Jill K Paterson; Joseph A Ludwig; Catherine Booth-Genthe; Michael M Gottesman
Journal:  Nat Rev Drug Discov       Date:  2006-03       Impact factor: 84.694

10.  P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration.

Authors:  Tetsuo Yamagishi; Sumit Sahni; Danae M Sharp; Akanksha Arvind; Patric J Jansson; Des R Richardson
Journal:  J Biol Chem       Date:  2013-09-23       Impact factor: 5.157

View more
  2 in total

1.  Revisiting atenolol as a low passive permeability marker.

Authors:  Xiaomei Chen; Tim Slättengren; Elizabeth C M de Lange; David E Smith; Margareta Hammarlund-Udenaes
Journal:  Fluids Barriers CNS       Date:  2017-10-31

Review 2.  Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development.

Authors:  Yurong Lai; Xiaoyan Chu; Li Di; Wei Gao; Yingying Guo; Xingrong Liu; Chuang Lu; Jialin Mao; Hong Shen; Huaping Tang; Cindy Q Xia; Lei Zhang; Xinxin Ding
Journal:  Acta Pharm Sin B       Date:  2022-03-17       Impact factor: 14.903

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.